iShares Core MSCI Emerging Markets ETF vs Oruka Therapeutics Inc. Common Stock — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $77.19 (market cap $158.70B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 30.6× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is more actively traded (490,798 versus 9,865,871). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 59 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| IEMG | ORKA | |
|---|---|---|
Market Cap | $158.70B | $5.18B |
Volume | 9,865,871 | 490,798 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $113.08 |
52-Week Low | $64.72 | $26.19 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $4.31B |
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $80.22, down 0.51% with a bearish technical signal from moving averages. The ETF faces neutral oscillators but shows support at $79-80 levels. Recent news highlights IEMG's strong performance against peers like SCHE and VWO, with emerging markets attracting record inflows amid dollar weakness and tech sector exposure.
Outlook remains mixed: technical weakness contrasts with fundamental appeal via low-cost emerging market access and 35% trailing returns. Risks include concentration in tech, volatility, and expense ratio disadvantages versus competitors. Analyst sentiment leans cautious due to recent underperformance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →